[1] Ferlay J, Soerjomataram I, Dikshit R, et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.   doi: 10.1002/ijc.29210
[2] Center MM, Jemal A, Lortet-Tieulent J, et al.  International Variation in Prostate Cancer Incidence and Mortality Rates[J]. Eur Urol, 2012, 61(6): 1079-1092.   doi: 10.1016/j.eururo.2012.02.054
[3] Antonarakis ES, Lu CX, Wang H, et al.  AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer[J]. N Engl J Med, 2014, 371(11): 1028-1038.   doi: 10.1056/NEJMoa1315815
[4] Strosberg J, El-Haddad G, Wolin E, et al.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376(2): 125-135.   doi: 10.1056/NEJMoa1607427
[5] Wright GL Jr, Haley C, Beckett ML, et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues[J]. Urol Oncol, 1995, 1(1): 18-28.   doi: 10.1016/1078-1439(95)00002-Y
[6] Chang SS, Reuter VE, Heston WDW, et al.  Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature[J]. Cancer Res, 1999, 59(13): 3192-3198.
[7] Murga JD, Moorji SM, Han AQ, et al.  Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer[J]. Prostate, 2015, 75(3): 242-254.   doi: 10.1002/pros.22910
[8] Hope TA, Truillet C, Ehman EC, et al.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience[J]. J Nucl Med, 2017, 58(1): 81-84.   doi: 10.2967/jnumed.116.181800
[9] Kranzbühler B, Salemi S, Umbricht CA, et al.  Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells[J]. Prostate, 2018, 78(10): 758-765.   doi: 10.1002/pros.23522
[10] Rahbar K, Ahmadzadehfar H, Kratochwil C, et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients[J]. J Nucl Med, 2017, 58(1): 85-90.   doi: 10.2967/jnumed.116.183194
[11] Sokoloff RL, Norton KC, Gasior CL, et al.  A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine[J]. Prostate, 2000, 43(2): 150-157.   doi: 10.1002/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B
[12] Fendler WP, Rahbar K, Herrmann K, et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer[J]. J Nucl Med, 2017, 58(8): 1196-1200.   doi: 10.2967/jnumed.117.191023
[13] Sterzing F, Kratochwil C, Fiedler H, et al.  68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2016, 43(1): 34-41.   doi: 10.1007/s00259-015-3188-1
[14] van Leeuwen PJ, Stricker P, Hruby G, et al.  68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment[J]. BJU Int, 2016, 117(5): 732-739.   doi: 10.1111/bju.13397
[15] Rahbar K, Weckesser M, Huss S, et al.  Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer[J]. J Nucl Med, 2016, 57(4): 563-567.   doi: 10.2967/jnumed.115.169243
[16]

Thomas L, Balmus C, Ahmadzadehfar H, et al. Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT[J/OL]. Pharmaceuticals (Basel), 2017, 10(3): 68[2018-08-10]. https://www.ncbi.nlm.nih.gov/pubmed/28758969. DOI: 10.3390/ph10030068.
[17] Maurer T, Gschwend JE, Rauscher I, et al.  Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer[J]. J Urol, 2016, 195(5): 1436-1443.   doi: 10.1016/j.juro.2015.12.025
[18] Afshar-Oromieh A, Avtzi E, Giesel FL, et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 197-209.   doi: 10.1007/s00259-014-2949-6
[19] Fanti S, Minozzi S, Castellucci P, et al.  PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data[J]. Eur J Nucl Med Mol Imaging, 2016, 43(1): 55-69.   doi: 10.1007/s00259-015-3202-7
[20] Baum RP, Kulkarni HR, Schuchardt C, et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy[J]. J Nucl Med, 2016, 57(7): 1006-1013.   doi: 10.2967/jnumed.115.168443
[21]

Gaertner FC, Halabi K, Ahmadzadehfar H, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer[J/OL]. Oncotarget, 2017, 8(33): 55094-55103[2018-08-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589644/. DOI: 10.18632/oncotarget.19049.
[22] Rathke H, Giesel FL, Flechsig P, et al.  Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq[J]. J Nucl Med, 2018, 59(3): 459-465.   doi: 10.2967/jnumed.117.194209
[23] Kulkarni HR, Singh A, Schuchardt C, et al.  PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013[J]. J Nucl Med, 2016, 57(S3): S97-104.   doi: 10.2967/jnumed.115.170167
[24] Rahbar K, Boegemann M, Yordanova A, et al.  PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival[J]. Eur J Nucl Med Mol Imaging, 2018, 45(1): 12-19.   doi: 10.1007/s00259-017-3848-4
[25] Scarpa L, Buxbaum S, Kendler D, et al.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates[J]. Eur J Nucl Med Mol Imaging, 2017, 44(5): 788-800.   doi: 10.1007/s00259-016-3609-9
[26] Kabasakal L, Toklu T, Yeyin N, et al.  Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry[J]. Mol Imaging Radionucl Ther, 2017, 26(2): 62-68.   doi: 10.4274/mirt.08760
[27] Yadav MP, Ballal S, Tripathi M, et al.  Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer[J]. Nucl Med Commun, 2017, 38(1): 91-98.   doi: 10.1097/MNM.0000000000000606
[28]

Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer[J/OL]. Oncotarget, 2017, 8(2): 3581-3590[2018-08-10]. https://www.ncbi.nlm.nih.gov/pubmed/27683041. DOI: 10.18632/oncotarget.12240.
[29]

Yordanova A, Becker A, Eppard E, et al. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2017, 44(9): 1473-1479. DOI: 10.1007/s00259-017-3681-9.
[30] Kratochwil C, Giesel FL, Stefanova M, et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617[J]. J Nucl Med, 2016, 57(8): 1170-1176.   doi: 10.2967/jnumed.115.171397
[31] Scher HI, Morris MJ, Stadler WM, et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3[J]. J Clin Oncol, 2016, 34(12): 1402-1418.   doi: 10.1200/JCO.2015.64.2702
[32] Yadav MP, Ballal S, Tripathi M, et al.  177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment[J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 81-91.   doi: 10.1007/s00259-016-3481-7
[33] Rahbar K, Bode A, Weckesser M, et al.  Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer[J]. Clin Nucl Med, 2016, 41(7): 522-528.   doi: 10.1097/RLU.0000000000001240
[34] Rahbar K, Schmidt M, Heinzel A, et al.  Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis[J]. J Nucl Med, 2016, 57(9): 1334-1338.   doi: 10.2967/jnumed.116.173757
[35] Rahbar K, Bogeman M, Yordanova A, et al.  Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2018, 45(2): 243-246.   doi: 10.1007/s00259-017-3877-z
[36] Ahmadzadehfar H, Wegen S, Yordanova A, et al.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617[J]. Eur J Nucl Med Mol Imaging, 2017, 44(9): 1448-1454.   doi: 10.1007/s00259-017-3716-2
[37] Hofman MS, Violet J, Hicks RJ, et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(6): 825-833.   doi: 10.1016/S1470-2045(18)30198-0
[38] von Eyben FE, Roviello G, Kiljunen T, et al.  Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review[J]. Eur J Nucl Med Mol Imaging, 2018, 45(3): 496-508.   doi: 10.1007/s00259-017-3895-x
[39] Calopedos RJS, Chalasani V, Asher R, et al.  Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis[J]. Prostate Cancer Prostatic Dis, 2017, 20(3): 352-360.   doi: 10.1038/pcan.2017.23
[40] Ferdinandus J, Eppard E, Gaertner FC, et al.  Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617[J]. J Nucl Med, 2017, 58(2): 312-319.   doi: 10.2967/jnumed.116.178228
[41] Bräuer A, Grubert LS, Roll W, et al.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2017, 44(10): 1663-1670.   doi: 10.1007/s00259-017-3751-z
[42]

Ahmadzadehfar H, Schlolaut S, Fimmers R, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy[J/OL]. Oncotarget, 2017, 8(61): 103108-103116[2018-08-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732715/. DOI: 10.18632/oncotarget.21600.
[43] Heck MM, Retz M, D'Alessandria C, et al.  Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer[J]. J Urol, 2016, 196(2): 382-391.   doi: 10.1016/j.juro.2016.02.2969
[44] Rahbar K, Ahmadzadehfar H, Boegemann M.  177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?[J]. Eur J Nucl Med Mol Imaging, 2018, 45(3): 513-514.   doi: 10.1007/s00259-017-3892-0
[45]

Ahmadzadehfar H, Zimbelmann S, Yordanova A, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride[J/OL]. Oncotarget, 2017, 8(33): 55567-55574[2018-08-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589682/. DOI: 10.18632/oncotarget.15698.
[46]

Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study[J/OL]. EJNMMI Res, 2015, 5: 36[2018-08-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477007/. DOI: 10.1186/s13550-015-0114-2.
[47]

Ahmadzadehfar H, Eppard E, Kürpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer[J/OL]. Oncotarget, 2016, 7(11): 12477-12488[2018-08-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914299/. DOI: 10.18632/oncotarget.7245.